Skip to main content

Table 7 MTX efficacy in relation to prior disease duration, dose and route of administration

From: Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration

Publication

No of patients

Prior disease duration

MTX dose (route)

ACRpedi70 (%)/CID (%)

Treatment duration (months)

  

6

12

Ruperto 2004 [33]

595

2.7 yrs (mean)

10 ± 2.3 mg/m2 (78 % p.o.)

38/12b

 

40

 

14.5 ± 1.3 mg/m2 (s.c., i.m.)a

 

45/12.5b

40

 

28.5 ± 2.5 mg/m2 (s.c., i.m.)a

 

47.5/10b

Bartoli 2007 [61]

125

1.45 yrs (med)

10 mg/m2 (NA)

26.4/NA

 

Tynjala 2011 [62]c

20

1.5 mo (mean)

15–30 mg/m2 (p.o.,s.c.)

 

60/25

Klein 2012 [50]

259

1.1 yrs (med)

0,4 mg/kg (p.o.)

51/NA

66/NA

152

0.8 yrs (med)

0.42 mg/kg (s.c.)

53/NA

 

Bulatovič 2012 [13]

104

≥1 yrs

9.8 mg/m2 (NA)

38.5/NA

50/NA

Wallace 2012 [43]

43

5.2 mo (mean)

0.5 mg/kg (s.c.)

NA/23.3

NA/16.3

Moncrieffe2013 [51]

87

1.3 yrs (med)

10–15 mg/m2 (70 % p.o.)

56.3/NA

 

Pastore 2015 [53]

69

1.0 yrs (med)

15 mg/m2 (62 % p.o.)

52.2/NA

 

Fraňova 2016

55

3.5 mo (med)

14.2 mg/m2 (18 % p.o.)

50.9/30.9

70.9/56.4

  1. MTX, Methotrexate
  2. CID, Clinical Inactive Disease [40]
  3. NA, Not available
  4. aPatients were non-responders to the dose of 10 ± 2.3 mg/m2 after the first 6 months
  5. bCriteria for inactive disease: Absence of active arthritis and ESR < 20 mm/h
  6. cDose 15 mg/m2 orally, non-responders at 3 months switched to 30 mg/m2 s.c
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096